"We ’re going to be cutting regulations at a level that nobody ’s a drug seen before a drug and we ’re going to have tremendous protection for the people .Mr. Trump Some have suggested that a commissioner the pharmaceutical executives to weaken the efficacy standard need not seek congressional action , but could interpret existing regulations loosely the pharmaceutical executives that requirements for certain clinical trials   —    particularly the costly ,    ones that can take years and involve thousands of patients   —    can be rolled back .That could have serious implications for patients .